Thomas Lingelbach, Valneva CEO

Small biotech says its Covid-19 vac­cine spurs more an­ti­bod­ies than As­traZeneca’s. Will sup­ply deals come now?

In a first, a small run­ner-up vac­cine de­vel­op­er says its own Covid-19 jab has in­duced “su­pe­ri­or neu­tral­iz­ing an­ti­body titer lev­els” over As­traZeneca’s AZD1222 when pit­ted head-to-head in a Phase III tri­al.

That and non-in­fe­ri­or­i­ty in se­ro­con­ver­sion rate were the co-pri­ma­ry end­points of the tri­al, which re­cruit­ed 4,012 adult vol­un­teers across the UK.

But on the ex­plorato­ry end­point of Covid-19 case counts, Val­ne­va notes that both treat­ment groups saw a sim­i­lar num­ber of in­fec­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.